Post-marketing Registry Study of Infliximab for Injection in Chinese Pediatric Crohn's Disease Patients
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
Post-marketing registration of Infliximab for injection in Chinese pediatric Crohn's disease patients.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 6
Maximum Age: 17
Healthy Volunteers: f
View:
• Age ranged 6 to 17 years (both inclusive), no gender limitation.
• A clear diagnosis was made in children with moderate to severe active stage (PCDAI≥30) Crohn's disease refer to the expert consensus on the diagnosis and treatment of inflammatory bowel disease in children (2019 edition).
• Patients and/or their guardians must sign ICF, and the research agreement/ICF for data collection and data verification shall comply with local laws and regulations.
• The patient received infliximab for the first time.
Locations
Other Locations
China
Beijing Children's Hospital, Capital Medical University
RECRUITING
Beijing
Contact Information
Primary
Wu Jie
licli2860@sina.com
18940251108
Time Frame
Start Date: 2023-09-21
Estimated Completion Date: 2027-02
Participants
Target number of participants: 30
Treatments
Experimental: Infliximab
Infliximab for the treatment of Crohn's disease in children
Related Therapeutic Areas
Sponsors
Leads: Taizhou Mabtech Pharmaceutical Co.,Ltd